Download Citation
Article Source:
In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
Vassilakopoulou M,
Togun T,
Dafni U,
Cheng H,
Bordeaux J,
et al.
(2014)
In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients.
PLOS ONE 9(6): e99131.
https://doi.org/10.1371/journal.pone.0099131